Key facts
- It has raised $16.6M.
- Notable investors include Rijksdienst voor Ondernemend Nederland, Limburg Development and Investment Company, Brightlands Venture Partners, Limburg Business Development Fund, Mibiton — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Matisse Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Matisse Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Matisse Pharmaceuticals
Operator of a biotechnology company intended to do development of pharmaceutical therapies to help in the treatment of sepsis. The company engages in the research and development of treatments to treat disorders that are associated with fulminant inflammation such as sepsis and septic shock, enabling healthcare professionals to avail advanced drugs to provide better treatment to the targeted patients.
- Sector
- Healthcare
- HQ
- Geleen, Netherlands
- Founded
- 2014
- Employees
- 14
- Website
- matissepharmaceuticals.com/
- Ownership
- Privately Held (backing)
Matisse Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Matisse Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Matisse Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.